ImmunoPrecise Advances Universal Dengue Vaccine, Confirming Safety, Immune Activation, and Structural Stability Using its LENSai™ Platform Powered by Patented HYFT® Technology
Follow-Up to June 5, 2025, Announcement Demonstrates Validated Vaccine Candidate with Strong Translational Potential
Article content
AUSTIN, Texas — ImmunoPrecise (NASDAQ: IPA), a leader in AI-driven biotherapeutics, provides a significant update following its June 5, 2025, press release ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery. This new release details the downstream validation of the epitope identified in that initial announcement—demonstrating that the computationally selected vaccine target is not only highly conserved across all four dengue virus types but also safe, immunologically active, and structurally stable.
Article content
Article content
'This is a major step forward,' said Dr. Jennifer Bath, CEO of ImmunoPrecise. 'Our AI technology not only found a new target for a universal dengue vaccine, but we've now shown it's safe and can trigger the right immune response. With this validation, we're excited to move ahead and advance this candidate toward the next stages of vaccine development.'
Article content
Following the recent discovery of a unique 'Achilles' heel' shared by all four types of dengue virus, ImmunoPrecise has confirmed—using its patented HYFT technology and LENS ai Immunogenicity Screener—that the selected target not only remains conserved but also triggers a strong and specific immune response. This breakthrough may pave the way for a safer, more universal dengue vaccine.
Article content
The new target was discovered using the Company's proprietary LENS ai platform. 'Our ability to move from computational discovery to AI-guided immunogenicity validation is unique to our methodology and drug development,' commented Dr. Jennifer Bath, ImmunoPrecise CEO. 'Further, it ensures that our candidates are both theoretically promising and primed for real-world immune protection, a critical requirement for any viable vaccine candidate.'
Article content
For decades, dengue has been one of the most challenging viruses for vaccine developers, largely because the virus comes in four different forms—and beating one doesn't guarantee protection from the others. Many vaccines fail because they trigger the immune system to attack the wrong parts of the virus, or worse, make infections more severe. What makes this development so important is that ImmunoPrecise's target has now been shown—based on in silico immune profiling—to likely engage key components of the immune system, including both B cells and T cells, in a manner that appears safe and highly specific. ImmunoPrecise's latest AI-driven testing shows that their selected target—a small, stable piece of the virus—can activate the body's defenses in a very precise way, without the risks of traditional, broader approaches.
Article content
A Methodology That Changes the Game—Far Beyond Dengue
Article content
What sets ImmunoPrecise apart is not only the discovery of a promising dengue vaccine target, but the methodology itself. With LENS ai powered by HYFT technology, IPA brings unprecedented clarity to the earliest stages of discovery—well before traditional disease modeling or animal studies even begin. By revealing deep relationships between sequence, structure, and function at the outset, this platform provides rapid, explainable insights that inform every downstream decision, from epitope selection to vaccine design.
Article content
The findings for dengue showcase the platform's versatility. Because HYFT technology systematically maps biological meaning across the entire biosphere, this methodology is readily transferable—equipping IPA to tackle a wide spectrum of infectious diseases, from HIV and influenza to emerging pathogens and oncology targets. With this approach, ImmunoPrecise isn't just keeping pace with the field; it's setting a new standard for how next-generation therapeutics are discovered and validated.
Article content
ImmunoPrecise's patented HYFT technology successfully identified a critical and discontiguous target site (epitope) that remains unchanged across all four types of dengue virus (DENV-1 through DENV-4). This target site is essential for how the virus infects cells and is believed to be key for establishing an enduring and efficacious universal dengue vaccine.
Article content
This HYFT-guided workflow achieves this by analyzing protein building blocks that may be far apart in the virus's genetic sequence but come together when the protein folds into its final 3D shape. This advanced mapping process combines genetic similarity analysis with 3D structural modeling and functional annotation to identify the most promising vaccine targets.
Article content
Complete Immune Response Testing Computer-based immune response screening used advanced prediction tools to evaluate how both antibody-producing cells (B cells) and infection-fighting cells (T cells) would respond to the vaccine target. The target site showed strong predicted binding to multiple human immune system markers (HLA class I and II types). This suggests that people from diverse backgrounds and genetic makeups could mount a strong immune response to the vaccine—something essential for global deployment.
Article content
Safety Verification Against Human Proteins Using ImmunoPrecise's proprietary retrieve-and-relate technology at the core of HYFT™ ( Van Hyfte et al., 2023, bioRxiv), the vaccine target was thoroughly compared against all known human and mouse proteins. This comprehensive safety check goes beyond standard comparison methods—HYFT systematically searches for not only genetic similarities but also structural and functional matches across species, ensuring the vaccine target is unique to the virus and not found in human biology. This is critical in vaccine development, where off-target effects can lead to dangerous autoimmune reactions. No problematic similarities were found, significantly reducing the risk that the vaccine would accidentally attack the body's own healthy cells.
Article content
Structural Stability Analysis Advanced computer modeling and molecular simulation studies have confirmed that the vaccine target maintains its proper shape, remains accessible to immune cells, and remains prominently displayed on the surface of the dengue virus. Stability testing demonstrated that the target remains robust under normal physiological conditions.
Article content
Balanced Immune Response Profile Importantly, the moderate predicted immune response strength (compared to typical vaccine 'hotspots') may explain why this target was overlooked in previous laboratory studies that focused on more obvious, highly immunogenic sites. This balanced profile suggests the vaccine could trigger a highly specific immune response while potentially reducing the risk of dangerous immune overreactions or antibody-dependent enhancement (ADE)—a serious complication that can worsen dengue infection.
Article content
Looking Ahead
Article content
This release is the second in a series of disclosures aimed at showcasing the power of ImmunoPrecise's end-to-end AI-native platform. The June 5th announcement introduced a promising target; today's release provides the crucial next step: a rigorous validation of that target's safety and immunological relevance. This validation significantly strengthens the translational potential of the candidate, which is currently being prepared for further preclinical evaluation.
Article content
These findings come at an important time, as global agencies continue to seek safer and more effective dengue vaccines. IPA is actively engaging with key stakeholders to explore the path forward, including potential collaboration, development, and funding partnerships.
Article content
About ImmunoPrecise Antibodies Ltd.
Article content
ImmunoPrecise (NASDAQ: IPA) is a global leader in AI-powered biotherapeutic discovery and development. Its proprietary HYFT technology and LENSai™ platform enable first-principles-based drug design, delivering validated therapeutic candidates across modalities and therapeutic areas. IPA partners with 19 of the top 20 pharmaceutical companies and is advancing next-generation biologics through data-driven, human-relevant models.
Article content
Forward-Looking Statements
Article content
This press release contains forward-looking statements within the meaning of applicable United States and Canadian securities laws. Forward-looking statements are often identified by words such as 'expects,' 'intends,' 'plans,' 'anticipates,' 'believes,' or similar expressions, or by statements that certain actions, events, or results 'may,' 'will,' 'could,' or 'might' occur or be achieved. These statements include, but are not limited to, statements regarding the anticipated benefits, scalability, and broader application of the LENSai™ and HYFT® platforms to dengue vaccine development; the advancement, regulatory acceptance, and future clinical potential of AI-native approaches for dengue and other infectious diseases; and the Company's ability to achieve and maintain scientific, regulatory, and commercial progress in its dengue program.
Article content
Forward-looking statements are based on management's current expectations, assumptions, and projections about future events. Actual results may differ materially from those expressed or implied due to a variety of factors, many of which are beyond the Company's control. These factors include, but are not limited to, the pace of scientific and technological developments, changes in regulatory requirements or acceptance of AI
Article content
designed vaccines, competition and market dynamics, intellectual property protection, risks related to preclinical or clinical validation of dengue vaccine candidates, integration and operational challenges, and changes in global economic or business conditions.
Article content
Forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause actual results, performance, or achievements to differ materially from those expressed or implied herein. Additional information regarding risks and uncertainties is included in the Company's Annual Report on Form 20-F, as amended, for the year ended April 30, 2024 (available on the Company's SEDAR+ profile at
Article content
www.sedarplus.ca
Article content
). Should any of these risks materialize, actual results could vary significantly from those currently anticipated.
Article content
Article content
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
27 minutes ago
- National Post
Invest in Precision: Mitutoyo America Corporation Announces Limited-Time Savings on MiSTAR 555 and 575 Coordinate Measuring Machines
Article content Sorry, your browser doesn't support embedded videos. Article content AURORA, Ill. — In today's unpredictable economy, one investment still delivers lasting certainty: Precision is the smartest investment. For a limited time, Mitutoyo America Corporation, the trusted leader in advanced metrology solutions, is offering a rare opportunity to invest in the future success of your inspection capabilities with exclusive promotional pricing of up to 26 percent off the MiSTAR 555 and 575 CMM through September 30, 2025. Article content Article content 'The MiSTAR CMM is built to thrive on the shop floor. It is rugged, reliable and fully adaptable to your machining process. With this exclusive promotion, you're not just getting precision, you're getting value with savings of up to 26 percent.' Article content Mitutoyo's MCOSMOS software scales to meet your inspection needs, from basic measurement and reporting with MCOSMOS-1, to CAD model part programming with free-form surface evaluation MCOSMOS-2 and MCOSMOS-3 adds scanning of 2D line and 3D surface profiles with CAD model analysis. Article content Three configurations offered: Article content BASIC model type- PH6 TP20 probing and MCOSMOS-1 software for small shops with essential digital routines Advanced model type- PH6M SP25 probe and MCOSMOS-2 software for growing operations who require CAD model part programming with free-form surface evaluation. Ultimate model type- PH10 SP25 MCOSMOS-3 software for high-throughput environments Article content The Mitutoyo MiSTAR CMM delivers reliable performance across a broad range of operating environments with guaranteed accuracy from 10 °C to 40 °C, and enhanced capability within narrower ranges of 10 °C to 30 °C and 18 °C to 22 °C. Article content Each MiSTAR configuration is delivered ready for immediate operation and includes: Article content When accuracy matters, manufacturers turn to Mitutoyo for proven performance that drives quality forward. Contact your local Mitutoyo representative or distributor to schedule a demo, consultation, or get a quote. Article content At Article content , precision is our profession. We are the leader in metrology instruments, solutions and support, offering more than 5,500 products, the largest and most comprehensive product portfolio of any commercial metrology provider. Mitutoyo also has the highest-performing A2LA-accredited calibration laboratories (A2LA Certificate No. 0750.01) in the nation. For more information, contact the Mitutoyo inside sales team at Article content Article content Article content Article content Article content Contacts
CTV News
27 minutes ago
- CTV News
Weight loss medications like Ozempic linked to eating disorders in boys and men: study
Prescription weight loss medication use has been linked to significantly higher rates of eating disorders in adolescent boys and men, according to a new study. Led by Kyle Ganson, an assistant professor at the University of Toronto's faculty of social work, the study focuses on an often overlooked population and raises new concerns about the use of high-profile medications like Ozempic and Wegovy for weight loss. 'While these medications are typically prescribed for diabetes or obesity, their off-label use for weight loss has become popular,' Ganson said in a news release from the University of Toronto. 'Our findings underscore potential psychological implications for young men.' The study analyzed survey data from 1,543 boys and men from Canada and the U.S. who were between the ages of 15 and 35. While only 1.2 per cent of the sample reported using prescription weight loss medication in the past 12 months, they were much more likely to report eating disorder attitudes and behaviours than others, such as loss of control while eating (63.2 per cent versus 36.2 per cent), binge eating (63.2 per cent versus 34.1 per cent) and purging via vomiting (15.8 per cent versus 5.6 per cent). The study also found that boys and men who used the medication were typically older, had a higher body mass index, and were more likely to identify as not being white or heterosexual. 'Boys and men are frequently left out of the conversation about eating disorders and body image pressures, but this study makes clear that they are not immune to the risks,' Ganson said. The study was published earlier this month in the journal Eating Behaviors. 'There is a greater need to describe the prevalence of use among understudied populations, as well as identify associations with eating disorder attitudes and behaviours,' the study explained. 'Health and mental health care professionals should be cognizant of the associations found in this study to ensure proper eating disorder assessment and intervention are provided to individuals, including boys and men, who use prescription weight loss medication.'
CTV News
27 minutes ago
- CTV News
Morgan Stanley stays bullish on U.S. stocks
In this Oct. 18, 2011, file photo, the Morgan Stanley logo is displayed on its Times Square building, in New York. (AP Photo/Mark Lennihan, File) Morgan Stanley backed its bullish stance on U.S. equities on Monday, citing strong earnings momentum, and said it was expecting a modest pullback in the third quarter that could create an opportunity to buy the dip. The Wall Street brokerage is leaning more towards its bull case of the benchmark S&P 500 hitting 7,200 points by the middle of the year, it wrote in a note. In May, the brokerage said the S&P 500 was expected to hit 6,500 in the second quarter of 2026. 'With earnings on solid footing into next year and the Fed closer to cutting rates, valuations can remain supported around current levels (~22x) as we think about the 12-month outlook,' Morgan Stanley equity strategists led by Michael Wilson said. However, the brokerage said rising Treasury yields - especially the 10-year note US10YT=RR breaching above 4.5% - could increase rate sensitivity for equities and an underperformance of rate-sensitive stocks such as small caps. Morgan Stanley also expects tariff-related cost pressures to show up later this year, which could impact company margins and bump up inflation, leading to a change in rate cut expectations by the Federal Reserve. Lastly, it estimates that seasonal trends may hit stocks in from mid-July through August. However, the brokerage said it would buy the dips as the risks could be temporary and only lead to a mild consolidation. Jefferies also raised its S&P 500 year-end target to 5,600 from its previous forecast of 5,300, according to the brokerage's note published on Friday. (Reporting by Shashwat Chauhan in Bengaluru; Editing by Anil D'Silva)
